Core Viewpoint - Picard Medical, Inc. has transitioned to public markets and is committed to advancing its Total Artificial Heart technology for patients with end-stage heart failure [1][2]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is based in Tucson, Arizona and is the leader in total artificial heart technology for end-stage heart failure patients [3]. - SynCardia has developed the SynCardia Total Artificial Heart (STAH), the first artificial heart approved by both the FDA and Health Canada, and remains the only commercially available artificial heart in the U.S. and Canada [3]. - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and studied artificial heart globally [3]. Transition to Public Markets - The company will ring the Opening Bell at the New York Stock Exchange on December 18, 2025, marking its transition to being a publicly traded entity [1]. - The CEO of Picard Medical expressed pride in this transition, emphasizing that it strengthens the company's ability to advance its artificial heart platform, including the fully implantable Emperor system [2]. Future Outlook - The transition to a public company is seen as an important phase for Picard Medical, as it aims to build on decades of clinical leadership and create long-term value through the advancement of next-generation technology [2].